A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-I 002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For,Cardiovascular Disease Who Are Statin Intolerant

StatusActive
Effective start/end date13/02/17 → 13/02/21

Funding

  • Esperion Therapeutics, Inc.: $18,425.40
View all
View less

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research